ERBB2 and glioblastoma: Several clinical trials are ongoing to assess the safety and efficacy of CAR‐T cells using different GBM‐associated antigens such as EGFRvIII, NKG2D, B7‐H3, CD147, IL13Ralpha2, and HER2.